Page 6 - Phase I News Today : Breaking News, Live Updates & Top Stories | Vimarsana

The Public Utility Commission of Texas is making quick changes to electricity grid and...

No longer concealed behind stone gates and hedges, the museum’s grounds now have a...

Earlier this week, news broke that the borders between the U.S. and Mexico — as well as...

Grifols to launch trial for potential COVID-19 therapy The subcutaneously administered immunoglobulin, if successful, would provide rapid immunity against the virus behind the deadly global pandemic. Biopharmaceutical firm Grifols, which specializes in development of therapies harnessing plasma-derived proteins, has announced it is kicking off a clinical trial in Spain to test the viability of a potential COVID-19 treatment. Based on the company’s immunoglobulin Gamunex-C and containing polyclonal antibodies, the drug at the center of the study reportedly has the...

The immunotherapy-focused firm reports enrollment stands at 55% for its ongoing study exploring viability of Ampion as an inhalable COVID-19 treatment. Ampio Pharmaceuticals, a company specializing in immunology-based therapies for inflammatory conditions, has announced that its ongoing Phase I clinical trial in the US, exploring inhalation treatment of COVID-19 with Ampion (AP-014), is now 55% enrolled. The trial is looking at the impact of inhaled Ampion treatments in patients suffering respiratory distress as a result of COVID-19 infection. Inhaled Ampion specif...